| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/08/2022 | Surface Oncology, Inc. | SURF | Grant | Stock Option (Right to Buy) | 24k | $2.01 | $48.2k | | 06/08/2022 |
| 06/07/2022 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 43k | $0.73 | $31.4k | | 06/07/2022 |
| 12/13/2021 | Aeglea BioTherapeutics, Inc. | AGLE | Purchase | Common Stock | 14.7k | $3.65 | $53.6k | | 12/09/2021 |
| 12/10/2021 | Aeglea BioTherapeutics, Inc. | AGLE | Purchase | Common Stock | 13.5k | $3.65 | $49.3k | | 12/09/2021 |
| 12/09/2021 | Aeglea BioTherapeutics, Inc. | AGLE | Purchase | Common Stock | 121.8k | $3.67 | $446.8k | | 12/09/2021 |
| 06/08/2021 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 40k | $6.80 | $272k | | 06/08/2021 |
| 06/08/2021 | Surface Oncology, Inc. | SURF | Grant | Stock Option (Right to Buy) | 17.7k | $7.69 | $136.1k | | 06/08/2021 |
| 06/10/2020 | Surface Oncology, Inc. | SURF | Grant | Stock Option (Right to Buy) | 12k | $4.35 | $52.2k | | 06/10/2020 |
| 06/08/2020 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 28.1k | $8.89 | $249.8k | | 06/08/2020 |
| 10/01/2019 | Surface Oncology, Inc. | SURF | Grant | Stock Option (Right to Buy) | 16.5k | $1.17 | $19.3k | | 10/01/2019 |
| 06/07/2019 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 12.4k | $6.33 | $78.5k | | 06/07/2019 |
| 06/05/2019 | Surface Oncology, Inc. | SURF | Grant | Stock Option (Right to Buy) | 12.1k | $3.69 | $44.6k | | 06/05/2019 |
| 06/21/2018 | AILERON THERAPEUTICS INC | ALRN | Grant | Stock Option (right to buy) | 10k | $6.02 | $60.2k | | 06/21/2018 |
| 06/07/2018 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 18.4k | $10.28 | $189.2k | | 06/07/2018 |
| 05/29/2018 | Protagonist Therapeutics, Inc | PTGX | Grant | Stock Option (right to buy) | 12k | $6.98 | $83.8k | | 05/29/2018 |
| 04/23/2018 | Surface Oncology, Inc. | SURF | Conversion | Common Stock | 3.2M | $0.00 | $0 | See Footnote | 04/23/2018 |
| 04/23/2018 | Surface Oncology, Inc. | SURF | Purchase | Common Stock | 266k | $15.00 | $4M | See Footnote | 04/23/2018 |
| 04/23/2018 | Surface Oncology, Inc. | SURF | Conversion | Series A Preferred Stock | 7M | $0.00 | $0 | See Footnote | 04/23/2018 |
| 12/01/2017 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 30k | $4.73 | $141.9k | | 12/01/2017 |
| 05/17/2016 | Aeglea BioTherapeutics, Inc. | AGLE | Grant | Director Stock Option (right to buy) | 24k | $7.28 | $174.7k | | 05/17/2016 |